title: HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
abstract: The success in the development of anti-retroviral therapies (HAART) that contain human immunodeficiency virus type 1 (HIV-1) infection is challenged by the cost of this lifelong therapy and by its toxicity. Immune-based therapeutic strategies that boost the immune response against HIV-1 proteins or protein subunits have been recently proposed to control virus replication in order to provide protection from disease development, reduce virus transmission, and help limit the use of anti-retroviral treatments. HIV-1 matrix protein p17 is a structural protein that is critically involved in most stages of the life cycle of the retrovirus. Besides its well established role in the virus life cycle, increasing evidence suggests that p17 may also be active extracellularly in deregulating biological activities of many different immune cells that are directly or indirectly involved in AIDS pathogenesis. Thus, p17 might represent a promising target for developing a therapeutic vaccine as a contribution to combating AIDS. In this article we review the biological characteristics of HIV-1 matrix protein p17 and we describe why a synthetic peptide representative of the p17 functional epitope may work as a vaccine molecule capable of inducing anti-p17 neutralizing response against p17 derived from divergent HIV-1 strains.
authors.affiliation: Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, 25123 Brescia, Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Fiorentini
authors.forename: Cinzia
authors.initials: C
authors.lastname: Giagulli
authors.forename: Francesca
authors.initials: F
authors.lastname: Caccuri
authors.forename: Anna K
authors.initials: AK
authors.lastname: Magiera
authors.forename: Arnaldo
authors.initials: A
authors.lastname: Caruso
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000628:therapy*; D023241:Antiretroviral Therapy, Highly Active; D004353:Drug Evaluation, Preclinical; D000939:Epitopes / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology* / Q000502:physiology*; D015497:HIV-1 / Q000276:immunology* / Q000502:physiology; D054298:Human Immunodeficiency Virus Proteins / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D010455:Peptides / Q000276:immunology; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000276:immunology* / Q000502:physiology*
chemical_list: D016915:AIDS Vaccines; D000939:Epitopes; D015483:HIV Antibodies; D015488:HIV Antigens; D054298:Human Immunodeficiency Virus Proteins; D010455:Peptides; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1